Stoke Therapeutics (STOK) Enterprise Value: 2022-2025
Historic Enterprise Value for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $1.0 billion.
- Stoke Therapeutics' Enterprise Value rose 109.16% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $217.5 million, marking a year-over-year increase of 384.03%. This contributed to the annual value of $367.3 million for FY2024, which is 996.99% up from last year.
- Latest data reveals that Stoke Therapeutics reported Enterprise Value of $1.0 billion as of Q3 2025, which was up 179.44% from $372.0 million recorded in Q2 2025.
- Over the past 5 years, Stoke Therapeutics' Enterprise Value peaked at $1.0 billion during Q3 2025, and registered a low of -$40.3 million during Q3 2023.
- Over the past 3 years, Stoke Therapeutics' median Enterprise Value value was $367.3 million (recorded in 2024), while the average stood at $325.5 million.
- As far as peak fluctuations go, Stoke Therapeutics' Enterprise Value slumped by 115.85% in 2023, and later skyrocketed by 1,331.76% in 2024.
- Stoke Therapeutics' Enterprise Value (Quarterly) stood at $134.4 million in 2022, then tumbled by 75.08% to $33.5 million in 2023, then spiked by 996.99% to $367.3 million in 2024, then spiked by 109.16% to $1.0 billion in 2025.
- Its Enterprise Value stands at $1.0 billion for Q3 2025, versus $372.0 million for Q2 2025 and $2.3 million for Q1 2025.